Using hematopoietic stem cell (CD34) and myeloid maturation (CD14 and CD206) markers, three HLA-A*01:01-positive patient-derived AML samples with DNMT3AR882H were shown to contain mixes of immature and mature malignant cell populations (Figure 6B). This evidence concerns the gene CD14 and acute myeloid leukemia.